Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol.

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Jeroen H A Creemers; Inka Pawlitzky; Konstantina Grosios; Uzi Gileadi; Mark R. Middleton; Winald R. Gerritsen; Niven Mehra; Licia Rivoltini; Ian Walters; Carl G. Figdor; Petronella B. Ottevanger; I. Jolanda M. de Vries

Journal title: BMJ Open

Journal number: 5

Journal publisher: BMJ Publishing Group

Published year: 2021

DOI identifier: 10.1136/bmjopen-2021-050725

ISSN: 2044-6055